House Appropriations Committee urges FDA to accelerate IND approvals for clinical trials

The House Appropriations Committee issued a directive to the Food and Drug Administration, calling for reforms to speed up the Investigational New Drug (IND) sign-off process for new clinical trials.

The move is part of a broader effort to keep the United States competitive with China and other nations in developing medical innovations, according to the committee’s statement.

The committee’s request does not specify particular timelines or regulatory changes, but signals congressional pressure for the FDA to streamline its review procedures.